UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
VKTX
Viking Therapeutics, Inc.
There isn't enough reported data to score VKTX yet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
VKTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
VKTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
VKTX PE Valuation
VKTX has no meaningful PE right now: it lost money over the past year.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
VKTX Forward outlook
There aren't enough analyst estimates for VKTX to show an outlook.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over VKTX on earnings quality, reporting a profit while its opponent remains loss making.
VKTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.41 | -$3.28 |
| Q2 2026 | -$4.67 | -$3.13 |
| Q1 2026 | -$4.15 | -$2.99 |
| Q4 2025 | -$3.19 | -$2.18 |
| Q3 2025 | -$2.13 | -$1.21 |
| Q2 2025 | -$1.54 | -$0.61 |
| Q1 2025 | -$1.16 | -$0.24 |
| Q4 2024 | -$1.01 | -$0.10 |
VKTX lost $5.41 per share over the past year, and its loss has widened in each of the last eight quarters.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over VKTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
VKTX Quarterly Revenue
VKTX's revenue is shrinking: $0 last quarter.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over VKTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
VKTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$138.2M | -$44.2M |
| Q2 2026 | -$125.2M | -$78.1M |
| Q1 2026 | -$114M | -$61.6M |
| Q4 2025 | -$85.3M | -$54.1M |
| Q3 2025 | -$94M | -$72M |
| Q2 2025 | -$47.1M | -$18.5M |
| Q1 2025 | -$52.3M | -$46.2M |
| Q4 2024 | -$31.2M | -$13.5M |
VKTX has burned cash in almost every quarter: −$463M over the past year, against −$225M the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over VKTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
VKTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +1.8M shares |
| 1 year | +5.1% | +5.7M shares |
| 3 years | +18% | +18.2M shares |
| 5 years | +51% | +40M shares |
| Available history | +64% | +46.1M shares |
VKTX has 118M diluted shares, up 5.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $1.7M |
| Q1 2022 | $5.1M |
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
VKTX Net Leverage
VKTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
VKTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.7 | Neutral |
| Stochastic | 17.7 | Oversold |
VKTX's weekly RSI is 45 (neutral) and its Stochastic is 18 (oversold).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
VKTX PE vs Healthcare Sector
VKTX has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over VKTX on trend strength, trading above more of its moving averages.
VKTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.2 | 2.1% below |
| 20 week MA | $31.7 | 13% below |
| 50 week MA | $32.4 | 15% below |
| 100 week MA | $31.7 | 13% below |
| 200 week MA | $33.9 | 19% below |
VKTX is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over VKTX on returns for 2026, with the stronger performance.
VKTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.33 | $6.20 | -26% |
| 2021 | $6.20 | $5.18 | -16% |
| 2022 | $5.18 | $8.45 | +63% |
| 2023 | $8.45 | $18.6 | +120% |
| 2024 | $18.6 | $41.2 | +121% |
| 2025 | $41.2 | $37.2 | -9.7% |
| 2026 YTD | $37.2 | $27.6 | -26% |
VKTX has finished lower in three of the last six years. It's down 26% so far in 2026.